AssetMark Inc
ZNTL icon

AssetMark Inc’s Zentalis Pharmaceuticals ZNTL Stock Holding History

AssetMark Inc’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,054
Closed -$30K – 1643
2022
Q2 		$30K Buy
1,054
+813
+337% +$21.5K ﹤0.01% 1040
2022
Q1 		$11K Buy
+241
New +$13K ﹤0.01% 1187

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

AssetMark Inc's ZNTL Position: Q3 2022 in Review

AssetMark Inc sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2022, closing a stake of 1,054 shares — an estimated $30K sold.

AssetMark Inc first reported a position in ZNTL in Q1 2022 and held it in 2 quarters. The position peaked at $30K in Q2 2022. 120 funds tracked by Wall St. Rank hold ZNTL as of Q3 2022.

  • AssetMark Inc reported no remaining Zentalis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • AssetMark Inc sold 1,054 Zentalis Pharmaceuticals shares in Q3 2022, an estimated $30K.
  • AssetMark Inc first reported a position in Zentalis Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • AssetMark Inc's Zentalis Pharmaceuticals position peaked at $30K in Q2 2022.
  • 120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2022.

Based on AssetMark Inc's 13F filing for Q3 2022, filed 1 Nov 2022.